Combination of G100 with KEYTRUDA (pembrolizumab) Triggers ... - GlobeNewswire (press release)
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers ... GlobeNewswire (press release) SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today presented data from the randomized Phase 2 trial of its investigational ...
What our clients and candidates are saying about us: THANK YOU!! I starting working with a couple of recruiters, however you really did stand out. I am HAPPY that my signing was with you, as it has been a pleasure to work with you as well. - Nicole
The #1 Resource for professionals in the Pharmaceutical Advertising, Medical Communications, Healthcare Public Relations, Pharmaceutical Industry, and Biotechnology fields since 1988.